Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Patrys Ltd

PAB.AX ✓ COMPLIANTFree checks used up today ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.02

▲ +0.00%

Market Cap $13.28M · Vol 7.39K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$13.28M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

N/A

YoY

RSI (14)

33.33

Momentum

Beta

2.45

vs Market

52W High

$0.04

46.49% below

52W Low

$0.02

20.80% above

Volume

7.39K

Avg 404.29K

P/B

2.51

Price-to-book

ROE

N/A

Return on equity

Free Float

69.83%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Patrys Ltd (PAB.AX) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PAB.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.45%

-15.15%

-24.32%

-3.45%

YTD

+0.00%

-6.67%

-58.37%

-93.40%

Financials & Valuation

TTM · Annual

Total Revenue	$6.22K
Net Income	$-2,363,136.00
Revenue Growth (YoY)	-93.18%
Gross Margin	100.00%
Operating Margin	-38,012.63%
Net Profit Margin	-38,012.63%
ROE	N/A
ROA · ROIC	-57.24% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	1,603.12
P/B	2.51
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	674.85M

Technical Indicators

50-Day SMA	$0.02
200-Day SMA	$0.02
RSI (14)	33.33
Beta	2.45
52-Week High	$0.04
52-Week Low	$0.02

Volume Today	7.39K
Avg Daily Volume (30D)	404.29K
Relative Volume	0.02x
Volatility (10D)	49.90
Volatility (30D)	67.47
Free Float	69.83%

Analyst Consensus

N/A

Current Price $0.02

Mean Target $0.09

52W Low$0.02 52W High$0.04

Current

Target

$0.02 $0.04

Current Analyst target

+367.72% upside potential · 0 analysts

Identifiers

ExchangeASX

FIGIBBG001SNQ2X7

ISINAU000000PAB9

CountryAustralia

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -6.02% ARGX.BR argenx SE -0.41% ARGX argenx SE -1.61% GMAB.CO Genmab A/S +1.30% GMAB Genmab A/S +1.09%

Company Profile

Patrys Limited is an Australia-based company. The Company is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. The Company’s deoxymab platform is based on the deoxymab 3E10 antibody that is identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). It has developed two humanized forms of deoxymab 3E10, called PAT-DX1 and PAT-DX3, which have improved activity over the original 3E10 antibody. PAT-DX1 is a dimer of a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10. PAT-DX3 is a humanized, full-sized antibody that has been further optimized to improve its therapeutic potential. It is also focused on developing RLS-2201, a proprietary injectable formulation of quetiapine.